ENO2 and neoplasm: Serum tumor marker sensitivity was 28.46% (35 patients) for CEA, 19.51% (24 patients) for CA 125, 3.25% (4 patients) for NSE, 50.41% (62 patients) for CYFRA 21‐1, 26.02% (32 patients) for SCC, and 11.38% (14 patients) for Pro‐GRP.